Medicine Division, Yangzhou Vocational College of Environment Resources, Yangzhou 225127, China.
Int Immunopharmacol. 2012 Dec;14(4):606-12. doi: 10.1016/j.intimp.2012.09.010. Epub 2012 Sep 30.
Diabetic retinopathy is a complex disease that has potential involvement of inflammatory in its pathogenesis. We hypothesized that tacrolimus (FK506), one of the potent immunosuppressive agent, could be effective against diabetic retinopathy, which involves significant inflammation. The aim of the present study was to investigate the effects of FK506 in early retinal changes of streptozotocin-induced diabetic mice. The effect of FK506 treatment (10 μg per eye for one week) was evaluated by TNF-a, VEGF, iNOS and COX-2 protein levels measurement, neovascularization, and the activation of NF-kB in the retina. Increased amounts of cytokines, neovascularization, inflammatory markers and activation of NF-kB were observed in retina from diabetic mice. FK506 treatment significantly lowered retinal TNF-a, VEGF, iNOS and COX-2. Further, treatment with FK506 significantly suppressed diabetes-related neovascularization, as well as the activation of NF-kB. These data demonstrated that FK506 attenuates the degree of retinal inflammation and preserving the neovascularization in early diabetic mice.
糖尿病性视网膜病变是一种复杂的疾病，其发病机制可能涉及炎症。我们假设，他克莫司（FK506），一种强效的免疫抑制剂，可能对涉及显著炎症的糖尿病性视网膜病变有效。本研究的目的是研究 FK506 对链脲佐菌素诱导的糖尿病小鼠早期视网膜变化的影响。通过 TNF-a、VEGF、iNOS 和 COX-2 蛋白水平的测量、新生血管形成和 NF-kB 在视网膜中的激活来评估 FK506 治疗（每周每只眼 10μg，持续一周）的效果。糖尿病小鼠视网膜中观察到细胞因子、新生血管形成、炎症标志物和 NF-kB 激活的增加。FK506 治疗可显著降低视网膜 TNF-a、VEGF、iNOS 和 COX-2 的含量。此外，FK506 治疗可显著抑制糖尿病相关的新生血管形成以及 NF-kB 的激活。这些数据表明，FK506 可减轻早期糖尿病小鼠视网膜炎症的程度并维持新生血管化。
